Arguably, even relatively recent studies published on reputable journals [26] keep restricting the study focus on the IGF-I/IGF-IR axis as a standalone system in cancer without including parallel analysis of the IGF-II/IRA ligand/RTK system in their experimental design [27], reiterating the persistence of an unsupported bias in the interpretation of the available experimental and observational data. The gene discussed is IGF2; the disease is cancer.